Home › Companies › AGIOS PHARMACEUTICALS INC. › 2024-2025

AGIOS PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and AGIOS PHARMACEUTICALS INC.’s Form 8-K, filed 2025-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.

6Reported items
246Asset managers
1,389Fund votes
2025-06-18Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AGIOS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by AGIOS PHARMACEUTICALS INC.

These tallies are AGIOS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AGIOS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2025-06-18
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Jacqualyn A. Fouse, Ph.D.	45,959,402	--	--	3,925,859	1,475,062	Majority: yes
Elect Director: David Scadden, M.D.	46,204,689	--	--	3,680,572	1,475,062	Majority: yes
2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.	46,843,926	3,024,905	16,430	--	1,475,062	Majority: yes
3. The Company's stockholders approved the 2023 Plan Amendment.	31,683,420	18,197,324	4,517	--	1,475,062	Majority: yes
4. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.	51,200,808	136,734	22,781	--	0	Majority: yes

Source: AGIOS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-06-18 — read the filing on EDGAR.

How asset managers voted at the AGIOS PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 246 asset managers that disclosed a AGIOS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of AGIOS PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To vote, on an advisory basis, to approve the compensation paid to our named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 46,843,926AGAINST: 3,024,905

AGIOS PHARMACEUTICALS INC.’s own tally for this item (“2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.”): 46,843,926 for, 3,024,905 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,886,781 outstanding shares: 81% for, 5% against (86% of the company cast a for/against vote).

The 243 asset managers below cast 96% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 95%

FOR: 94.7%AGAINST: 4.3%ABSTAIN: 0.0%SPLIT: 1.1%

Largest asset managers voting on “To vote, on an advisory basis, to approve the compensation paid to our named executive officers.” at AGIOS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	6,259,447	477	For
FARALLON CAPITAL MANAGEMENT LLC	5,072,130	0	For
BlackRock	4,621,890	0	For
T. Rowe Price	4,040,251	0	For
State Street	3,429,871	0	For
Erste Asset Management GmbH	2,304,900	0	For
Commodore Capital LP	2,291,637	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	1,694,299	0	For
Fidelity	1,553,409	0	For
Delaware/Macquarie	1,537,387	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,406,164	0	For
Frazier Life Sciences Management, L.P.	1,279,754	0	For
JPMorgan	1,213,416	0	For
BNP Paribas Asset Management Holding S.A.	0	964,812	Against
Charles Schwab	947,110	0	For
Fisher Asset Management, LLC	855,721	0	For
GW&K Investment Management, LLC	252,139	0	Split
ArrowMark Colorado Holdings LLC	772,307	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	743,000	0	For
Artisan	655,972	0	For
Caligan Partners LP	578,827	0	For
SCS Capital Management LLC	551,348	0	For
Northern Trust	518,794	0	For
Rock Springs Capital Management LP	342,180	0	For
PICTET ASSET MANAGEMENT SA	299,262	0	For

Showing the 25 largest of 243 asset managers. See all 243 in the interactive database.

2. To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: David Scadden, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%7%

FOR: 46,204,689WITHHELD: 3,680,572

AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: David Scadden, M.D.”): 46,204,689 for, 3,680,572 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,886,781 outstanding shares: 80% for, 6% withheld (86% of the company cast a for/withheld vote).

The 73 asset managers below cast 100% of the shares they voted on this item FOR (18,800,340 for, 0 against).

FOR 93%

FOR: 18,800,340 (93.5%)ABSTAIN: 1,313,512 (6.5%)

Largest asset managers voting on “To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a thr” at AGIOS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	6,116,254	0	For
BlackRock	2,553,677	0	For
Erste Asset Management GmbH	2,304,900	0	For
T. Rowe Price	1,751,483	0	For
Delaware/Macquarie	1,537,387	0	For
Fidelity	1,536,298	0	For
State Street	4,835	1,151,992	Abstain
Charles Schwab	473,555	0	For
JPMorgan	291,784	0	For
Artisan	280,695	0	For
AMG FUNDS	196,273	0	For
Equitable	106,768	60,110	For
TIAA	151,019	0	For
MERIDIAN FUND INC	147,936	0	For
American Century	120,474	0	For
QUANTITATIVE MASTER SERIES LLC	96,562	0	For
WisdomTree	90,637	0	For
Northern Trust	64,334	0	For
Goldman Sachs	61,531	0	For
Lincoln Financial	19,674	41,500	Abstain
GuideStone	55,647	0	For
Invesco	0	54,918	Abstain
Brighthouse	52,484	1,894	For
Columbia Threadneedle	50,585	0	For
Direxion Shares ETF Trust	47,331	0	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

3. To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified: Jacqualyn A. Fouse, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 45,959,402WITHHELD: 3,925,859

AGIOS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jacqualyn A. Fouse, Ph.D.”): 45,959,402 for, 3,925,859 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,886,781 outstanding shares: 79% for, 7% withheld (86% of the company cast a for/withheld vote).

The 73 asset managers below cast 88% of the shares they voted on this item FOR (16,527,263 for, 2,304,900 against).

FOR 82%11%

FOR: 16,527,263 (82.2%)AGAINST: 2,304,900 (11.5%)ABSTAIN: 1,281,689 (6.4%)

Largest asset managers voting on “To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a thr” at AGIOS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	6,115,777	0	477	For
BlackRock	2,553,677	0	0	For
Erste Asset Management GmbH	0	2,304,900	0	Against
T. Rowe Price	1,751,483	0	0	For
Delaware/Macquarie	1,537,387	0	0	For
Fidelity	1,536,298	0	0	For
State Street	4,812	0	1,152,015	Abstain
Charles Schwab	473,555	0	0	For
JPMorgan	291,784	0	0	For
Artisan	280,695	0	0	For
AMG FUNDS	196,273	0	0	For
Equitable	106,768	0	60,110	For
TIAA	151,019	0	0	For
MERIDIAN FUND INC	147,936	0	0	For
American Century	120,474	0	0	For
QUANTITATIVE MASTER SERIES LLC	96,562	0	0	For
WisdomTree	90,637	0	0	For
Northern Trust	64,334	0	0	For
Goldman Sachs	61,531	0	0	For
Lincoln Financial	19,674	0	41,500	Abstain
GuideStone	55,647	0	0	For
Invesco	54,918	0	0	For
Brighthouse	52,484	0	1,894	For
Columbia Threadneedle	50,585	0	0	For
Direxion Shares ETF Trust	47,331	0	0	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

4. To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%

FOR: 51,200,808AGAINST: 136,734

AGIOS PHARMACEUTICALS INC.’s own tally for this item (“4. The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.”): 51,200,808 for, 136,734 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,886,781 outstanding shares: 88% for, 0.3% against (89% of the company cast a for/against vote).

The 73 asset managers below cast 99.9% of the shares they voted on this item FOR (20,095,207 for, 16,751 against).

FOR 99.9%

FOR: 20,095,207 (99.9%)AGAINST: 16,751 (0.1%)ABSTAIN: 1,894 (0.0%)

Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm f” at AGIOS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	6,116,254	0	0	For
BlackRock	2,553,677	0	0	For
Erste Asset Management GmbH	2,304,900	0	0	For
T. Rowe Price	1,751,483	0	0	For
Delaware/Macquarie	1,537,387	0	0	For
Fidelity	1,536,298	0	0	For
State Street	1,156,758	69	0	For
Charles Schwab	473,555	0	0	For
JPMorgan	291,784	0	0	For
Artisan	280,695	0	0	For
AMG FUNDS	196,273	0	0	For
Equitable	166,878	0	0	For
TIAA	151,019	0	0	For
MERIDIAN FUND INC	147,936	0	0	For
American Century	120,474	0	0	For
QUANTITATIVE MASTER SERIES LLC	96,562	0	0	For
WisdomTree	90,637	0	0	For
Northern Trust	64,334	0	0	For
Goldman Sachs	61,531	0	0	For
Lincoln Financial	61,174	0	0	For
GuideStone	55,647	0	0	For
Invesco	54,918	0	0	For
Brighthouse	52,484	0	1,894	For
Columbia Threadneedle	50,585	0	0	For
Direxion Shares ETF Trust	47,331	0	0	For

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

5. TO APPROVE AN AMENDMENT TO THE AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AVAILABLE THEREUNDER BY 2,500,000 SHARES.

COMPENSATIONMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

64% Majority: yes · of votes cast

FOR 64%AGAINST 36%

FOR: 31,683,420AGAINST: 18,197,324

AGIOS PHARMACEUTICALS INC.’s own tally for this item (“3. The Company's stockholders approved the 2023 Plan Amendment.”): 31,683,420 for, 18,197,324 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 57,886,781 outstanding shares: 54.7% for, 31% against (86% of the company cast a for/against vote).

The 71 asset managers below cast 84% of the shares they voted on this item FOR (14,894,607 for, 2,878,363 against).

FOR 84%AGAINST 16%

FOR: 14,894,607 (83.8%)AGAINST: 2,878,363 (16.2%)ABSTAIN: 1,894 (0.0%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE AGIOS PHARMACEUTICALS, INC. 2023 STOCK INCENTIVE PLAN, TO INCREASE THE NUMBER O” at AGIOS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	6,112,654	3,600	0	For
BlackRock	2,553,677	0	0	For
T. Rowe Price	1,751,483	0	0	For
Delaware/Macquarie	0	1,537,387	0	Against
Fidelity	1,294,335	241,963	0	For
State Street	1,155,331	1,496	0	For
Charles Schwab	473,555	0	0	For
JPMorgan	291,784	0	0	For
Artisan	0	280,695	0	Against
AMG FUNDS	0	196,273	0	Against
Equitable	166,878	0	0	For
TIAA	151,019	0	0	For
MERIDIAN FUND INC	147,936	0	0	For
American Century	0	120,474	0	Against
QUANTITATIVE MASTER SERIES LLC	96,562	0	0	For
WisdomTree	90,637	0	0	For
Northern Trust	64,334	0	0	For
Goldman Sachs	47,555	13,976	0	For
Lincoln Financial	41,500	19,674	0	For
Invesco	54,918	0	0	For
Brighthouse	31,140	21,344	1,894	For
Columbia Threadneedle	0	50,585	0	Against
Direxion Shares ETF Trust	0	47,331	0	Against
John Hancock	23,868	20,060	0	For
ALPS ETF Trust	0	42,419	0	Against

Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.

6. Amend Omnibus Stock Plan

COMPENSATIONMajority of the votes cast: yes

64% Majority: yes · of votes cast

FOR 64%AGAINST 36%

FOR: 31,683,420AGAINST: 18,197,324

The 4 asset managers below cast 98% of the shares they voted on this item FOR (2,304,900 for, 56,583 against).

FOR 98%

FOR: 2,304,900 (97.6%)AGAINST: 56,583 (2.4%)

Largest asset managers voting on “Amend Omnibus Stock Plan” at AGIOS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Erste Asset Management GmbH	2,304,900	0	For
GuideStone	0	55,647	Against
HC CAPITAL TRUST	0	892	Against
UNIFIED SERIES TRUST	0	44	Against

Largest AGIOS PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of AGIOS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 57,886,781 shares outstanding at the time of that meeting.

Top AGIOS PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	10.81%
2	FARALLON CAPITAL MANAGEMENT LLC	8.76%
3	BlackRock	7.98%
4	T. Rowe Price	6.98%
5	State Street	5.93%
6	Erste Asset Management GmbH	3.98%
7	Commodore Capital LP	3.96%
8	MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	2.93%
9	Fidelity	2.68%
10	Delaware/Macquarie	2.66%

Reported AGIOS PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

AGIOS PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	9.68%	13F
BlackRock	8.83%	13F
Farallon Partners, L.L.C.	8.72%	13G
Lynx1 Capital Management LP	5.21%	13G
State Street	4.23%	13F
T. Rowe Price	3.98%	13F
Geode Capital	2.41%	13F
Dimensional Fund Advisors	2.18%	13F
JPMorgan Chase	1.81%	13F
Goldman Sachs	1.14%	13F

Percentages above are of 57,886,781 shares outstanding, as reported by AGIOS PHARMACEUTICALS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AGIOS PHARMACEUTICALS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At AGIOS PHARMACEUTICALS INC.'s shareholder meeting held 2025-06-18, in the 2024-2025 proxy season, 246 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,389 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To vote, on an advisory basis, to approve the compensation paid to our named executive officers. — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: AGIOS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-18.

AGIOS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.